Students Unveil AI Creations At University Of Auckland Hackathon
University of Auckland students unveiled their artificial intelligence creations – prototypes for AI agents – at a weekend hackathon, the culmination of their Master of Artificial Intelligence (MAI) course.
In the novel, high-pressure event, 21 teams presented proof-of-concept AI agents to a panel of judges from IBM and the University on campus on 7-8 June.
The AI tools were designed and developed over five weeks to address real-world challenges facing researchers and universities in New Zealand and overseas.
'It's what they'll be doing in real life – collaborating with colleagues to get the most out of the AI tools available and solve real-world problems' says Dr Thomas Lacombe, the director of the MAI programme. 'We were impressed with what we saw.'
The AI agents – a term for software systems that use AI to complete tasks – were developed using IBM watsonx. The tools would help researchers by:
providing initial feedback on proposals for research funding;
pre-screening ethics applications for human and animal research;
and advising on export permit requirements for sensitive research.
'We were delighted to be able to partner with the Master of Artificial Intelligence team and IBM on this hackathon,' said Nick Kearns, of the University's Research and Innovation Office. 'It was great to see the students demonstrate secure and scalable solutions.'
The University will investigate supporting the students in developing the tools for implementation, Kearns says.
The students, who took part in teams of four or five, are part of the second cohort for the Master of Artificial Intelligence programme, which debuted last year, teaching AI through academic, technical, ethical and business lenses.
Technical support for the hackathon was provided by IBM mentors and ElementX, as well as subject matter experts and researchers from across the University.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
20 hours ago
- RNZ News
Approaching life-changing diagnosis for "missing millions" with ME/CFS
Photo: Professor Warren Tate Photo: Supplied Anyone who has or knows someone with ME, chronic syndrome fatigue or long covid knows that being believed is one of the toughest parts of having the condition. University of Otago Emeritus Professor Warren Tate has dedicated his life to researching ME/CFS and is considered a leading authority on long covid. Along with his team, he has been developing a diagnostic test, that so far has shown promising results. If implemented, it would be life-changing. Warren and his co-researcher Dr Katie Peppercorn have also released a one-of-a-kind book to help clinicians and researchers find ways of better understanding post-viral conditions and improve the lives of those 'missing millions' affected with ME/CFS and most recently long covid.
RNZ News
20 hours ago
- RNZ News
Approaching life-changing diagnosis for 'missing millions'
Photo: Professor Warren Tate Photo: Supplied Anyone who has or knows someone with ME, chronic syndrome fatigue or long covid knows that being believed is one of the toughest parts of having the condition. University of Otago Emeritus Professor Warren Tate has dedicated his life to researching ME/CFS and is considered a leading authority on long covid. Along with his team, he has been developing a diagnostic test, that so far has shown promising results. If implemented, it would be life-changing. Warren and his co-researcher Dr Katie Peppercorn have also released a one-of-a-kind book to help clinicians and researchers find ways of better understanding post-viral conditions and improve the lives of those 'missing millions' affected with ME/CFS and most recently long covid.
Scoop
2 days ago
- Scoop
Clues To Diagnosing Parkinson's And MSA Discovered
Press Release – University of Auckland Australasian brain scientists have made a breakthrough that could help to diagnose Parkinson's disease and multiple system atrophy (MSA). Researchers at the University of Auckland's Centre for Brain Research – Dr Victor Dieriks and Dr James Wiseman – and University of Sydney Professor Glenda Halliday have discovered distinctive markers in the brains of people with the two diseases, which are often mistaken for one another in the early stages. 'It's vital to be able to accurately distinguish between Parkinson's and MSA early on, because this directly impacts on treatment decisions and patients' well-being,' says Dieriks. Currently, diagnosis of Parkinson's and MSA is based on patients' symptoms. Misdiagnosis often occurs, because the two conditions have similar symptoms. 'When misdiagnosed, patients with MSA are often given the Parkinson's drug, levodopa, which not only fails to help, but can worsen symptoms in some cases,' says Dieriks. While both conditions affect movement, Parkinson's typically progresses slowly with tremors, muscle stiffness, and slowness of movement. In contrast, MSA advances rapidly and includes problems such as severe balance issues, and disturbances in blood pressure and heart rate. The team used an innovative technique to study donated brain tissue in the Neurological Foundation Human Brain Bank in Auckland and the Sydney Brain Bank. They focused on a protein involved in both diseases – -synuclein – and found distinctive patterns and levels in Parkinson's, compared with MSA. 'We discovered this protein clumps differently in the brains of people with Parkinson's and MSA and the levels in MSA are far higher,' says Dieriks. Their discovery could pave the way for a simple, non-invasive test, such as a nasal swab, blood test, or urine sample, to reliably tell the two conditions apart. Lead researcher Wiseman says it's a significant breakthrough to be able to definitively diagnose Parkinson's and MSA from brain tissue. 'What's really exciting is we're a step closer to being able to diagnose these disorders by using readily available body fluids. 'This means we could pick up Parkinson's and MSA early, potentially before people even start to experience symptoms,' says Wiseman. Parkinson's disease affects millions globally, while MSA is far rarer, impacting about five in every 100,000 people. But MSA's toll is devastating, says Dieriks. 'MSA can turn active, independent people into individuals needing full-time care within just a few years. 'Whereas people with Parkinson's may live for decades, those with MSA typically survive only three to ten years after symptoms begin,' says Dieriks. Globally, research on Parkinson's is progressing rapidly, he says. 'We're closer than ever to developing a diagnostic test for Parkinson's. And the sooner we can catch these diseases, the better chance we have of slowing or stopping their progression.'
